Court Place Advisors LLC Sells 77,445 Shares of OmniAb, Inc. (NASDAQ:OABI)

Court Place Advisors LLC reduced its position in OmniAb, Inc. (NASDAQ:OABI) by 76.7% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 23,556 shares of the company’s stock after selling 77,445 shares during the quarter. Court Place Advisors LLC’s holdings in OmniAb were worth $83,000 as of its most recent filing with the SEC.

Several other large investors also recently modified their holdings of the company. Murchinson Ltd. acquired a new stake in OmniAb during the 3rd quarter worth about $4,230,000. Dimensional Fund Advisors LP boosted its position in shares of OmniAb by 6.9% during the 2nd quarter. Dimensional Fund Advisors LP now owns 3,012,216 shares of the company’s stock valued at $11,296,000 after purchasing an additional 194,835 shares in the last quarter. Rice Hall James & Associates LLC grew its stake in OmniAb by 6.4% during the third quarter. Rice Hall James & Associates LLC now owns 2,722,321 shares of the company’s stock worth $11,515,000 after purchasing an additional 163,038 shares during the period. Squarepoint Ops LLC bought a new stake in OmniAb in the second quarter worth approximately $449,000. Finally, Barclays PLC lifted its stake in OmniAb by 321.5% in the third quarter. Barclays PLC now owns 143,215 shares of the company’s stock valued at $606,000 after buying an additional 109,236 shares during the period. 72.08% of the stock is currently owned by institutional investors and hedge funds.

OmniAb Stock Up 5.3 %

NASDAQ OABI opened at $3.37 on Tuesday. OmniAb, Inc. has a 52 week low of $3.11 and a 52 week high of $6.55. The business has a 50 day moving average price of $3.64 and a 200-day moving average price of $4.05. The company has a market cap of $475.90 million, a price-to-earnings ratio of -5.44 and a beta of -0.10.

Analyst Ratings Changes

Several brokerages have recently commented on OABI. HC Wainwright reaffirmed a “buy” rating and set a $11.00 price objective on shares of OmniAb in a research report on Thursday, November 14th. Benchmark restated a “buy” rating and issued a $8.00 price target on shares of OmniAb in a report on Thursday, November 14th.

Insider Buying and Selling at OmniAb

In other OmniAb news, insider Charles S. Berkman sold 25,489 shares of OmniAb stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $3.24, for a total transaction of $82,584.36. Following the completion of the transaction, the insider now owns 343,190 shares in the company, valued at approximately $1,111,935.60. The trade was a 6.91 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Matthew W. Foehr sold 41,811 shares of the business’s stock in a transaction that occurred on Tuesday, January 21st. The stock was sold at an average price of $3.24, for a total value of $135,467.64. Following the sale, the chief executive officer now directly owns 3,749,639 shares of the company’s stock, valued at $12,148,830.36. This represents a 1.10 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 82,826 shares of company stock worth $268,356. 8.60% of the stock is owned by corporate insiders.

About OmniAb

OmniAb, Inc, a biotechnology company, engages in the discovery and provision of therapeutic antibody discovery technologies in the United States. The company's technology platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners' drug development efforts.